View : 6 Download: 0

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

Title
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
Authors
Jensen, ThomasAbdelmalek, Manal F.Sullivan, ShelbyNadeau, Kristen J.Green, MelanieRoncal, CarlosNakagawa, TakahikoKuwabara, MasanariSato, YukaKang, Duk-HeeTolan, Dean R.Sanchez-Lozada, Laura G.Rosen, Hugo R.Lanaspa, Miguel A.Diehl, Anna MaeJohnson, Richard J.
Ewha Authors
강동훈
SCOPUS Author ID
강동훈scopus
Issue Date
2018
Journal Title
JOURNAL OF HEPATOLOGY
ISSN
0168-8278JCR Link1600-0641JCR Link
Citation
vol. 68, no. 5, pp. 1063 - 1075
Keywords
Hepatic steatosisHepatic inflammationInsulin resistanceSugar consumptionUric acid
Publisher
ELSEVIER SCIENCE BV
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome; its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and a sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high-fructose corn syrup [HFCS]) not only increase the risk of NAFLD, but also non-alcoholic steatohepatitis (NASH). Herein, we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. Recent evidence suggests that the predisposition to fatty liver is linked to the metabolism of fructose by fructokinase C, which results in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation. Alterations to gut permeability, the microbiome, and associated endotoxemia contribute to the risk of NAFLD and NASH. Early clinical studies suggest that reducing sugary beverages and total fructose intake, especially from added sugars, may have a significant benefit on reducing hepatic fat accumulation. We suggest larger, more definitive trials to determine if lowering sugar/HFCS intake, and/or blocking uric acid generation, may help reduce NAFLD and its downstream complications of cirrhosis and chronic liver disease. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
DOI
10.1016/j.jhep.2018.01.019
Appears in Collections:
연구기관 > 세포항상성연구센터 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE